Clinical Trials
27 trialsNCT06308263 2026-04-23
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT05683418 2026-04-22
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Totus Medicines
Phase 1 Recruiting
NCT06667141 2026-03-23
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Acrivon Therapeutics
Phase 1 Recruiting
NCT07064122 2026-03-02
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
AstraZeneca
Phase 1 Recruiting
NCT03423628 2025-12-22
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
Phase 1 Recruiting
NCT05159700 2025-12-15
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1 Active not recruiting
NCT07137637 2025-08-22
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Hangzhou Polymed Biopharmaceuticals, Inc.
Phase 1 Not yet recruiting
NCT01226316 2025-06-29
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Phase 1 Completed
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT03309150 2024-11-29
ATRi Transition Rollover Study
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT05246111 2024-11-22
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT04800822 2024-10-22
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT05764915 2024-08-01
A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
Regor Pharmaceuticals Inc.
Phase 1 Terminated
NCT04095273 2024-04-02
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Bayer
Phase 1 Completed
NCT04586335 2024-03-21
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
Phase 1 Terminated
NCT02961283 2023-05-09
Study of ASN003 in Subjects With Advanced Solid Tumors
Asana BioSciences
Phase 1 Terminated
NCT03730142 2023-04-18
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
Shanghai Jiatan Pharmatech Co., Ltd
Phase 1 Completed
NCT02292225 2023-02-27
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
SecuraBio
Phase 1 Terminated
NCT04330625 2022-11-08
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
Duke University
Phase 1 Terminated
NCT02684032 2022-07-27
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Celcuity Inc
Phase 1 Completed
NCT03074825 2019-07-24
Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1 Terminated
NCT00726583 2018-05-17
Phase I Trial of Oral PX-866
Seagen Inc.
Phase 1 Completed
NCT01341834 2018-04-24
Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors
National Cancer Centre, Singapore
Phase 1 Unknown
NCT01470209 2018-03-19
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Emory University
Phase 1 Completed
NCT01449370 2017-03-09
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
Takeda
Phase 1 Completed
NCT02598570 2017-02-06
Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
AbbVie
Phase 1 Completed
NCT00996892 2016-12-30
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Terminated